CoChat
Sign Up
Cited by 535Antioxidant Activity and Oxidative StressNitric Oxide and Endothelin EffectsRedox biology and oxidative stress

Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation

Open access
Ito, Fumiaki, Sono, Yoko, Ito, Tomoyuki·2019·Antioxidants
DOI 10.3390/antiox8030072PMC PMC6466575
Open this paper in CoChat — free accountOpen PDF

Abstract

Endothelial dysfunction is one of the initial steps in the pathogenesis of atherosclerosis and development of cardiovascular disease in patients with diabetes mellitus. Several risk factors are associated with endothelial dysfunction and atherosclerosis, such as hypertension, dyslipidaemia, inflammation, oxidative stress, and advanced glycation-end products. Among these risk factors, oxidative stress is the largest contributor to the formation of atherosclerotic plaques. Measurement of reactive oxygen species (ROS) is still difficult, and assays for the measurement of ROS have failed to show a consistent correlation between pathological states and oxidative stress. To solve this problem, this review summarizes the current knowledge on biomarkers of oxidative stress, especially lipid peroxidation, and discusses the roles of oxidative stress, as measured by indices of lipid peroxidation, in diabetes mellitus, atherosclerosis, and chronic inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antiox8030072

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 138

  1. [1]Radi R. Beckman J.S. Bush K.M. Freeman B.A. Peroxynitrite, a stealthy biological oxidant J. Biol. Chem. 2013 288 26464 26472 10.1074/jbc.R113.472936 23861390 PMC3772193 · DOI
  2. [2]Lushchak V.I. Free radicals, reactive oxygen species, oxidative stress and its classification Chem.-Biol. Interact. 2014 224 164 175 10.1016/j.cbi.2014.10.016 25452175 · DOI
  3. [3]McCord J.M. The evolution of free radicals and oxidative stress Am. J. Med. 2000 108 652 659 10.1016/S0002-9343(00)00412-5 10856414 · DOI
  4. [4]Li S. Tan H.Y. Wang N. Zhang Z.J. Lao L. Wong C.W. Feng Y. The role of oxidative stress and antioxidants in liver diseases Int. J. Mol. Sci. 2015 16 26087 26124 10.3390/ijms161125942 26540040 PMC4661801 · DOI
  5. [5]Maritim A.C. Sanders R.A. Watkins J.B. 3rd Diabetes, oxidative stress, and antioxidants: A review J. Biochem. Mol. Toxicol. 2003 17 24 38 10.1002/jbt.10058 12616644 · DOI
  6. [6]Bonomini F. Tengattini S. Fabiano A. Bianchi R. Rezzani R. Atherosclerosis and oxidative stress Histol. Histopathol. 2008 23 381 390 18072094
  7. [7]Niki E. Yoshida Y. Saito Y. Noguchi N. Lipid peroxidation: Mechanisms, inhibition, and biological effects Biochem. Biophys. Res. Commun. 2005 338 668 676 10.1016/j.bbrc.2005.08.072 16126168 · DOI
  8. [9]Fritz K.S. Petersen D.R. An overview of the chemistry and biology of reactive aldehydes Free Radic. Biol. Med. 2013 59 85 91 10.1016/j.freeradbiomed.2012.06.025 22750507 PMC3540155 · DOI · Paper page
  9. [10]Guo W. Adachi T. Matsui R. Xu S. Jiang B. Zou M.H. Kirber M. Lieberthal W. Cohen R.A. Quantitative assessment of tyrosine nitration of manganese superoxide dismutase in angiotensin II-infused rat kidney Am. J. Physiol. Heart Circ. Physiol. 2003 285 H1396 1403 10.1152/ajpheart.00096.2003 12791589 · DOI
  10. [11]Khan J. Brennand D.M. Bradley N. Gao B. Bruckdorfer R. Jacobs M. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method Biochem. J. 1998 330 795 801 10.1042/bj3300795 9480893 PMC1219208 · DOI
  11. [12]Dotan Y. Lichtenberg D. Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress Prog. Lipid Res. 2004 43 200 227 10.1016/j.plipres.2003.10.001 15003395 · DOI
  12. [13]Lichtenberg D. Pinchuk I. Oxidative stress, the term and the concept Biochem. Biophys. Res. Commun. 2015 461 441 444 10.1016/j.bbrc.2015.04.062 25911322 · DOI
  13. [14]Le N.A. Lipoprotein-associated oxidative stress: A new twist to the postprandial hypothesis Int. J. Mol. Sci. 2014 16 401 419 10.3390/ijms16010401 25548897 PMC4307253 · DOI
  14. [15]Morrow J.D. Roberts L.J. Daniel V.C. Awad J.A. Mirochnitchenko O. Swift L.L. Burk R.F. Comparison of formation of D2/E2-isoprostanes and F2-isoprostanes in vitro and in vivo--effects of oxygen tension and glutathione Arch. Biochem. Biophys. 1998 353 160 171 10.1006/abbi.1998.0645 9578611 · DOI
  15. [16]Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges Anal. Biochem. 2017 524 13 30 10.1016/j.ab.2016.10.021 27789233 · DOI · Paper page
  16. [17]Grimsrud P.A. Xie H. Griffin T.J. Bernlohr D.A. Oxidative stress and covalent modification of protein with bioactive aldehydes J. Biol. Chem. 2008 283 21837 21841 10.1074/jbc.R700019200 18445586 PMC2494933 · DOI
  17. [18]Pizzimenti S. Ciamporcero E. Daga M. Pettazzoni P. Arcaro A. Cetrangolo G. Minelli R. Dianzani C. Lepore A. Gentile F. Interaction of aldehydes derived from lipid peroxidation and membrane proteins Front. Physiol. 2013 4 242 10.3389/fphys.2013.00242 24027536 PMC3761222 · DOI
  18. [19]Slatter D.A. Murray M. Bailey A.J. Formation of a dihydropyridine derivative as a potential cross-link derived from malondialdehyde in physiological systems FEBS Lett. 1998 421 180 184 10.1016/S0014-5793(97)01554-8 9468302 · DOI
  19. [20]Lamore S.D. Azimian S. Hom D. Anglin B.L. Uchida K. Cabello C.M. Wondrak G.T. The malondialdehyde-derived fluorophore DHP-lysine is a potent sensitizer of UVA-induced photooxidative stress in human skin cells J. Photochem. Photobiol. B 2010 101 251 264 10.1016/j.jphotobiol.2010.07.010 20724175 PMC2963670 · DOI
  20. [21]Palinski W. Ord V.A. Plump A.S. Breslow J.L. Steinberg D. Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum Arterioscler. Thromb. 1994 14 605 616 10.1161/01.ATV.14.4.605 7511933 · DOI
  21. [22]Pratico D. Lawson J.A. FitzGerald G.A. Cylooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2α J. Biol. Chem. 1995 270 9800 9808 10.1074/jbc.270.17.9800 7730359 · DOI
  22. [23]Wang Z. Ciabattoni G. Créminon C. Lawson J. Fitzgerald G.A. Patrono C. Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man J. Pharmacol. Exp. Ther. 1995 275 94 100 7562601
  23. [24]Lawson J.A. Li H. Rokach J. Adiyaman M. Hwang S.W. Khanapure S.P. FitzGerald G.A. Identification of two major F2 isoprostanes, 8,12-iso- and 5-epi-8,12-iso-isoprostane F2α-VI, in human urine J. Biol. Chem. 1998 273 29295 29301 10.1074/jbc.273.45.29295 9792628 · DOI
  24. [25]Praticò D. Barry O.P. Lawson J.A. Adiyaman M. Hwang S.W. Khanapure S.P. Iuliano L. Rokach J. FitzGerald G.A. IPF2α-I: An index of lipid peroxidation in humans Proc. Natl. Acad. Sci. USA 1998 95 3449 3454 10.1073/pnas.95.7.3449 9520386 PMC19856 · DOI
  25. [26]Li H. Lawson J.A. Reilly M. Adiyaman M. Hwang S.W. Rokach J. FitzGerald G.A. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine Proc. Natl. Acad. Sci. USA 1999 96 13381 13386 10.1073/pnas.96.23.13381 10557329 PMC23956 · DOI
  26. [27]Bessard J. Cracowski J.L. Stanke-Labesque F. Bessard G. Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay J. Chromatogr. B Biomed. Sci. Appl. 2001 754 333 343 10.1016/S0378-4347(00)00621-6 11339277 · DOI
  27. [28]Davi G. Falco A. Patrono C. Lipid peroxidation in diabetes mellitus Antioxid. Redox Signal. 2005 7 256 268 10.1089/ars.2005.7.256 15650413 · DOI
  28. [29]Monnier L. Mas E. Ginet C. Michel F. Villon L. Cristol J.P. Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA 2006 295 1681 1687 10.1001/jama.295.14.1681 16609090 · DOI · Paper page
  29. [30]Proudfoot J.M. Barden A.E. Loke W.M. Croft K.D. Puddey I.B. Mori T.A. HDL is the major lipoprotein carrier of plasma F2-isoprostanes J. Lipid Res. 2009 50 716 722 10.1194/jlr.M800607-JLR200 19050315 PMC2656665 · DOI
  30. [31]Proudfoot J.M. Barden A.E. Croft K.D. Galano J.M. Durand T. Bultel-Poncé V. Giera M. Mori T.A. F2-isoprostanes in HDL are bound to neutral lipids and phospholipids Free Radic. Res. 2016 50 1374 1385 10.1080/10715762.2016.1250262 27750456 · DOI
  31. [32]Stafforini D.M. Sheller J.R. Blackwell T.S. Sapirstein A. Yull F.E. McIntyre M. Bonventre J.V. Prescott S.M. Roberts L.J. 2nd Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasmaplatelet-activating factor acetylhydrolases J. Biol. Chem. 2006 281 4616 4623 10.1074/jbc.M507340200 16371369 · DOI
  32. [33]Morrow J.D. Hill K.E. Burk R.F. Nammour T.M. Badr K.F. Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl. Acad. Sci. USA 1990 87 9383 9387 10.1073/pnas.87.23.9383 2123555 PMC55169 · DOI
  33. [34]Halliwell B. Lee C.Y. Using isoprostanes as biomarkers of oxidative stress: Some rarely considered issues Antioxid. Redox Signal. 2010 13 145 156 10.1089/ars.2009.2934 20001743 · DOI
  34. [35]Stiegel M.A. Pleil J.D. Sobus J.R. Angrish M.M. Morgan M.K. Kidney injury biomarkers and urinary creatinine variability in nominally healthy adults Biomarkers 2015 20 436 452 10.3109/1354750X.2015.1094136 26616147 · DOI
  35. [36]Bauer J. Ripperger A. Frantz S. Ergün S. Schwedhelm E. Benndorf R.A. Pathophysiology of isoprostanes in the cardiovascular system: Implications of isoprostane-mediated thromboxane A2 receptor activation Br. J. Pharmacol. 2014 171 3115 3131 10.1111/bph.12677 24646155 PMC4080968 · DOI
  36. [37]Praticó D. FitzGerald G.A. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2 J. Biol. Chem. 1996 271 8919 8924 10.1074/jbc.271.15.8919 8621535 · DOI
  37. [38]Delannoy E. Courtois A. Freund-Michel V. Leblais V. Marthan R. Muller B. Hypoxia-induced hyperreactivity of pulmonary arteries: Role of cyclooxygenase-2, isoprostanes, and thromboxane receptors Cardiovasc. Res. 2010 85 582 592 10.1093/cvr/cvp292 19710084 · DOI
  38. [39]Reilly M. Delanty N. Lawson J.A. FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers Circulation 1996 94 19 25 10.1161/01.CIR.94.1.19 8964113 · DOI
  39. [40]Tsikas D. Suchy M.T. Niemann J. Tossios P. Schneider Y. Rothmann S. Gutzki F.M. Frölich J.C. Stichtenoth D.O. Glutathione promotes prostaglandin H synthase (cyclooxygenase)-dependent formation of malondialdehyde and 15(S)-8-iso-prostaglandin F2α FEBS Lett. 2012 586 3723 3730 10.1016/j.febslet.2012.09.001 22982857 · DOI
  40. [41]Pilz J. Meineke I. Gleiter C.H. Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative J. Chromatogr. B Biomed. Sci. Appl. 2000 742 315 325 10.1016/S0378-4347(00)00174-2 10901136 · DOI
  41. [42]Wade C.R. Jackson P.G. Van Rij A.M. Quantitation of malondialdehyde (MDA) in plasma, by ion-pairing reverse phase high performance liquid chromatography Biochem. Med. 1985 33 291 296 10.1016/0006-2944(85)90003-1 4015630 · DOI
  42. [43]Yu L.W. Latriano L. Duncan S. Hartwick R.A. Witz G. High-performance liquid chromatography analysis of the thiobarbituric acid adducts of malonaldehyde and trans,trans-muconaldehyde Anal. Biochem. 1986 156 326 333 10.1016/0003-2697(86)90261-7 3766936 · DOI
  43. [44]Moselhy H.F. Reid R.G. Yousef S. Boyle S.P. A specific, accurate, and sensitive measure of total plasma malondialdehyde by HPLC J. Lipid Res. 2013 54 852 858 10.1194/jlr.D032698 23264677 PMC3617959 · DOI
  44. [45]Cordis G.A. Das D.K. Riedel W. High-performance liquid chromatographic peak identification of 2,4-dinitrophenylhydrazine derivatives of lipid peroxidation aldehydes by photodiode array detection J. Chromatogr. A 1998 798 117 123 10.1016/S0021-9673(97)01161-8 9542133 · DOI
  45. [46]Sobsey C.A. Han J. Lin K. Swardfager W. Levitt A. Borchers C.H. Development and evaluation of a liquid chromatography–mass spectrometry method for rapid, accurate quantitation of malondialdehyde in human plasma J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2016 1029–1030 205 212 10.1016/j.jchromb.2016.07.013 27437618 · DOI
  46. [47]Tsikas D. Rothmann S. Schneider J.Y. Suchy M.T. Trettin A. Modun D. Stuke N. Maassen N. Frölich J.C. Development, validation and biomedical applications of stable-isotope dilution GC-MS and GC-MS/MS techniques for circulating malondialdehyde (MDA) after pentafluorobenzyl bromide derivatization: MDA as a biomarker of oxidative stress and its relation to 15(S)-8-iso-prostaglandin F2α and nitric oxide (NO) J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2016 1019 95 111 26522895
  47. [48]Zelzer S. Oberreither R. Bernecker C. Stelzer I. Truschnig-Wilders M. Fauler G. Measurement of total and free malondialdehyde by gas–chromatography mass spectrometry—Comparison with high-performance liquid chromatography methology Free Radic. Res. 2013 47 651 656 10.3109/10715762.2013.812205 23745592 · DOI
  48. [49]Verde V. Fogliano V. Ritieni A. Maiani G. Morisco F. Caporaso N. Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma Free Radic. Res. 2002 36 869 873 10.1080/1071576021000005302 12420745 · DOI
  49. [50]Ito F. Ito T. Suzuki C. Yahata T. Ikeda K. Hamaoka K. The Application of a modified d-ROMs test for measurement of oxidative stress and oxidized high-density lipoprotein Int. J. Mol. Sci. 2017 18 454 10.3390/ijms18020454 PMC5343988 28230785 · DOI
  50. [51]Tang L. Zhang Y. Qian Z. Shen X. The mechanism of Fe2+-initiated lipid peroxidation in liposomes: The dual function of ferrous ions, the roles of the pre-existing lipid peroxides and the lipid peroxyl radical Biochem. J. 2000 352 27 36 10.1042/bj3520027 11062055 PMC1221429 · DOI
  51. [52]Rosenson R.S. Brewer H.B. Chapman J. Fazio S. Hussain M. Kontush A. Krauss R.M. Otvos J.D. Remaley A.T. Schaefer E.J. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events Clin. Chem. 2011 57 392 410 10.1373/clinchem.2010.155333 21266551 · DOI
  52. [53]Pirillo A. Norata G.D. Catapano A.L. High-density lipoprotein subfractions—What the clinicians need to know Cardiology 2013 124 116 125 10.1159/000346463 23428644 · DOI
  53. [54]Soran H. Schofield J.D. Durrington P.N. Antioxidant properties of HDL Front. Pharmacol. 2015 6 222 10.3389/fphar.2015.00222 26528181 PMC4607861 · DOI
  54. [55]Bonnefont-Rousselot D. Motta C. Khalil A.O. Sola R. La Ville A.E. Delattre J. Gardes-Albert M. Physicochemical changes in human high-density lipoprotein (HDL) oxidized by gamma radiolysis-generated oxyradicals. Effect on their cholesterol effluxing capacity Biochim. Biophys. Acta 1995 1255 23 30 10.1016/0005-2760(94)00211-G 7893734 · DOI
  55. [56]Kontush A. Chapman M.J. Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities Curr. Opin. Lipidol. 2010 21 312 318 10.1097/MOL.0b013e32833bcdc1 20581677 · DOI
  56. [57]Lűscher T.F. Landmesser U. von Eckardstein A. Fogelman A.M. High-density lipoprotein: Vascular protective effects, dysfunction, and potential as therapeutic target Circ. Res. 2014 114 171 182 10.1161/CIRCRESAHA.114.300935 24385510 · DOI
  57. [58]Rasmiena A.A. Barlow C.K. Ng T.W. Tull D. Meikle P.J. High density lipoprotein efficiently accepts surface but not internal oxidized lipids from oxidized low density lipoprotein Biochim. Biophys. Acta 2016 1861 69 77 10.1016/j.bbalip.2015.11.002 26569052 · DOI
  58. [59]Pandey K.B. Rizvi S.I. Biomarkers of oxidative stress in red blood cells Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2011 155 131 136 10.5507/bp.2011.027 21804621 · DOI
  59. [60]Nakagawa K. Kiko T. Hatade K. Sookwong P. Arai H. Miyazawa T. Antioxidant effect of lutein towards phospholipid hydroperoxidation in human erythrocytes Br. J. Nutr. 2009 102 1280 1284 10.1017/S0007114509990316 19622187 · DOI
  60. [62]Cade W.T. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting Phys. Ther. 2008 88 1322 1335 10.2522/ptj.20080008 18801863 PMC2579903 · DOI
  61. [64]Nathan D.M. Cleary P.A. Backlund J.Y. Genuth S.M. Lachin J.M. Orchard T.J. Raskin P. Zinman B. Diabetes control and complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N. Engl. J. Med. 2005 353 2643 2653 16371630 PMC2637991
  62. [65]Holman R.R. Paul S.K. Bethel M.A. Matthews D.R. Neil H. 10-year follow-up of intensive glucose control in type 2 diabetes N. Engl. J. Med. 2008 359 1577 1589 10.1056/NEJMoa0806470 18784090 · DOI · Paper page
  63. [66]Ceriello A. Postprandial hyperglycemia and cardiovascular disease is the HEART2D study the answer? Diabetes Care 2009 32 521 522 10.2337/dc08-2209 19246590 PMC2646040 · DOI
  64. [68]Juutilainen A. Lehto S. Rönnemaa T. Pyörälä K. Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects Diabetes Care 2008 31 714 719 10.2337/dc07-2124 18083789 · DOI
  65. [69]Davì G. Ciabattoni G. Consoli A. Mezzetti A. Falco A. Santarone S. Pennese E. Vitacolonna E. Bucciarelli T. Costantini F. In vivo formation of 8-iso prostaglandin F2α and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation Circulation 1999 99 224 229 10.1161/01.CIR.99.2.224 9892587 · DOI · Paper page
  66. [70]Sampson M.J. Gopaul N. Davies I.R. Hughes D.A. Carrier M.J. Plasma F2 isoprostanes: Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes Diabetes Care 2002 25 537 541 10.2337/diacare.25.3.537 11874943 · DOI
  67. [71]Davì G. Chiarelli F. Santilli F. Pomilio M. Vigneri S. Falco A. Basili S. Ciabattoni G. Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: Role of interleukin-6 and disease duration Circulation 2003 107 3199 3203 10.1161/01.CIR.0000074205.17807.D0 12810609 · DOI
  68. [72]Patrono C. Falco A. Davi G. Isoprostane formation and inhibition in atherothrombosis Curr. Opin. Pharmacol. 2005 5 198 203 10.1016/j.coph.2004.11.003 15780831 · DOI
  69. [73]Saisho Y. Glycemic variability and oxidative stress: A link between diabetes and cardiovascular disease? Int. J. Mol. Sci. 2014 15 18381 18406 10.3390/ijms151018381 25314300 PMC4227221 · DOI
  70. [74]Dailey G. Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A1c measurements Mayo Clin. Proc. 2007 82 229 235 10.1016/S0025-6196(11)61003-3 17290732 · DOI
  71. [75]DECODE Study Group, the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria Arch. Intern. Med. 2001 161 397 405 10.1001/archinte.161.3.397 11176766 · DOI · Paper page
  72. [77]Kodani N. Saisho Y. Tanaka K. Kawai T. Itoh H. Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus Clin. Drug Investig. 2013 33 563 570 10.1007/s40261-013-0098-5 23797928 · DOI
  73. [78]Yang S.-W. Park K.-H. Zhou Y.-J. The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology Angiology 2016 67 802 809 10.1177/0003319715623400 26685181 · DOI
  74. [79]Feldman-Billard S. Massin P. Meas T. Guillausseau P.J. Héron E. Hypoglycemia-induced blood pressure elevation in patients with diabetes Arch. Intern. Med. 2010 170 829 831 10.1001/archinternmed.2010.98 20458093 · DOI
  75. [80]Assaloni R. Da Ros R. Quagliaro L. Piconi L. Maier A. Zuodar G. Motz E. Ceriello A. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients Diabetologia 2005 48 1919 1924 10.1007/s00125-005-1849-5 16007412 · DOI
  76. [81]Ohara M. Fukui T. Ouchi M. Watanabe K. Suzuki T. Yamamoto S. Yamamoto T. Hayashi T. Oba K. Hirano T. Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes Diabetes Res. Clin. Pract. 2016 122 62 70 10.1016/j.diabres.2016.09.025 27810687 · DOI
  77. [82]Davignon J. Ganz P. Role of endothelial dysfunction in atherosclerosis Circulation 2004 109 III27 32 10.1161/01.CIR.0000131515.03336.f8 15198963 · DOI · Paper page
  78. [83]Allen J.D. Stabler T. Kenjale A.A. Ham K.L. Robbins J.L. Duscha B.D. Kraus W.E. Annex B.H. Diabetes status differentiates endothelial function and plasma nitrite response to exercise stress in peripheral arterial disease following supervised training J. Diabetes Complic. 2014 28 219 225 10.1016/j.jdiacomp.2013.08.002 24355663 PMC3943470 · DOI
  79. [84]González J. Valls N. Brito R. Rodrigo R. Essential hypertension and oxidative stress: New insights World J. Cardiol. 2014 6 353 366 10.4330/wjc.v6.i6.353 24976907 PMC4072825 · DOI
  80. [85]Davi G. Alessandrini P. Mezzetti A. Minotti G. Bucciarelli T. Costantini F. Cipollone F. Bon G.B. Ciabattoni G. Patrono C. In vivo formation of 8-epi prostaglandin F2α is increased in hypercholesterolemia Arterioscler. Thromb. Vasc. Biol. 1997 17 3230 3235 10.1161/01.ATV.17.11.3230 9409316 · DOI
  81. [87]Ye J. Mechanisms of insulin resistance in obesity Front. Med. 2013 7 14 24 10.1007/s11684-013-0262-6 23471659 PMC3936017 · DOI · Paper page
  82. [88]Hurrle S. Hsu W.H. The etiology of oxidative stress in insulin resistance Biomed. J. 2017 40 257 262 10.1016/j.bj.2017.06.007 29179880 PMC6138814 · DOI
  83. [89]Evans J.L. Goldfine I.D. Maddux B.A. Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003 52 1 8 10.2337/diabetes.52.1.1 12502486 · DOI · Paper page
  84. [90]Montezano A.C. Touyz R.M. Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases Basic Clin. Pharmacol. Toxicol. 2012 110 87 94 10.1111/j.1742-7843.2011.00785.x 21883939 · DOI
  85. [92]Bauer P.M. Fulton D. Boo Y.C. Sorescu G.P. Kemp B.E. Jo H. Sessa W.C. Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase J. Biol. Chem. 2003 278 14841 14849 10.1074/jbc.M211926200 12591925 · DOI
  86. [93]Montagnani M. Chen H. Barr V.A. Quon M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179 J. Biol. Chem. 2001 276 30392 30398 10.1074/jbc.M103702200 11402048 · DOI
  87. [94]Rees D.D. Palmer R.M. Schulz R. Hodson H.F. Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo Br. J. Pharmacol. 1990 101 746 752 10.1111/j.1476-5381.1990.tb14151.x 1706208 PMC1917753 · DOI
  88. [95]Ting H. Timimi F.K. Boles K.S. Creager S.J. Ganz P. Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus J. Clin. Investig. 1996 97 22 28 10.1172/JCI118394 8550838 PMC507058 · DOI
  89. [96]Tesfamariam B. Brown M.L. Cohen R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C J. Clin. Investig. 1991 87 1643 1648 10.1172/JCI115179 2022734 PMC295254 · DOI
  90. [97]Williams S.B. Goldfine A.B. Timimi F.K. Ting H.H. Roddy M.A. Simonson D.C. Creager M.A. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo Circulation 1998 97 1695 1701 10.1161/01.CIR.97.17.1695 9591763 · DOI
  91. [98]Sandoo A. van Zanten J.J. Metsios G.S. Carroll D. Kitas G.D. The endothelium and its role in regulating vascular tone Open Cardiovasc. Med. J. 2010 4 302 312 10.2174/1874192401004010302 21339899 PMC3040999 · DOI
  92. [99]Miyoshi T. Ito H. Assessment of arterial stiffness using the cardio-ankle vascular index Pulse (Basel) 2016 4 11 23 10.1159/000445214 27493899 PMC4949370 · DOI
  93. [101]Kawano H. Motoyama T. Hirashima O. Hirai N. Miyao Y. Sakamoto T. Kugiyama K. Ogawa H. Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery J. Am. Coll. Cardiol. 1999 34 146 154 10.1016/S0735-1097(99)00168-0 10400004 · DOI · Paper page
  94. [102]Beckman J.A. Goldfine A.B. Gordon M.B. Creager M.A. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans Circulation 2001 103 1618 1623 10.1161/01.CIR.103.12.1618 11273987 · DOI
  95. [103]Ceriello A. Taboga C. Tonutti L. Quagliaro L. Piconi L. Bais B. Da Ros R. Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment Circulation 2002 106 1211 1218 10.1161/01.CIR.0000027569.76671.A8 12208795 · DOI · Paper page
  96. [105]Risso A. Mercuri F. Quagliaro L. Damante G. Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture Am. J. Physiol. Endocrinol. Metab. 2001 281 E924 E930 10.1152/ajpendo.2001.281.5.E924 11595647 · DOI
  97. [106]Azuma K. Kawamori R. Toyofuku Y. Kitahara Y. Sato F. Shimizu T. Miura K. Mine T. Tanaka Y. Mitsumata M. Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta Arterioscler. Thromb. Vasc. Biol. 2006 26 2275 2280 10.1161/01.ATV.0000239488.05069.03 16888238 · DOI
  98. [107]Manzato E. Zambon A. Lapolla A. Zambon S. Braghetto L. Crepaldi G. Fedele D. Lipoprotein abnormalities in well-treated type II diabetic patients Diabetes Care 1993 16 469 475 10.2337/diacare.16.2.469 8432219 · DOI
  99. [108]Lyons T.J. Jenkins A.J. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: A carbonyl stress hypothesis Diabetes Rev. (Alex) 1997 5 365 391 26366051 PMC4567260
  100. [109]Njajou O.T. Kanaya A.M. Holvoet P. Connelly S. Strotmeyer E.S. Harris T.B. Cummings S.R. Hsueh W.C. Health ABC Study Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study Diabetes Metab. Res. Rev. 2009 25 733 739 10.1002/dmrr.1011 19780064 PMC3269343 · DOI
  101. [110]Nakhjavani M. Khalilzadeh O. Khajeali L. Esteghamati A. Morteza A. Jamali A. Dadkhahipour S. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol Lipids 2010 45 321 327 10.1007/s11745-010-3401-8 20224977 · DOI
  102. [111]Tsimikas S. Clopton P. Brilakis E.S. Marcovina S.M. Khera A. Miller E.R. de Lemos J.A. Witztum J.L. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race, apolipoprotein(a) isoform size and cardiovascular risk factors: Results from the Dallas Heart Study Circulation 2009 119 1711 1719 10.1161/CIRCULATIONAHA.108.836940 19307470 PMC2782388 · DOI
  103. [112]Miller N.E. Thelle D.S. Forde O.H. Mjos O.D. The Tromsø Heart Study: High-density lipoprotein and coronary heart disease: A prospective case-control study Lancet 1977 1 965 968 10.1016/S0140-6736(77)92274-7 67464 · DOI
  104. [113]Ashen M.D. Blumenthal R.S. Clinical practice: Low HDL cholesterol levels N. Engl. J. Med. 2005 353 1252 1260 10.1056/NEJMcp044370 16177251 · DOI
  105. [115]Wang N. Tall A.R. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux Arterioscler. Thromb. Vasc. Biol. 2003 23 1178 1184 10.1161/01.ATV.0000075912.83860.26 12738681 · DOI
  106. [117]Ragbir S. Farmer J.A. Dysfunctional high-density lipoprotein and atherosclerosis Curr. Atheroscler. Rep. 2010 12 343 348 10.1007/s11883-010-0091-x 20506005 · DOI
  107. [118]Farbstein D. Levy A.P. HDL dysfunction in diabetes: Causes and possible treatments Expert Rev. Cardiovasc. Ther. 2012 10 353 361 10.1586/erc.11.182 22390807 PMC3332215 · DOI
  108. [119]Duell P.B. Oram J.F. Bierman E.L. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux Diabetes 1991 40 377 384 10.2337/diab.40.3.377 1847886 · DOI
  109. [120]Zhou H. Tan K.C. Shiu S.W. Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy Nephrol. Dial. Transplant. 2008 23 927 933 10.1093/ndt/gfm631 18065800 · DOI
  110. [121]Zheng L. Nukuna B. Brennan M.L. Sun M. Goormastic M. Settle M. Schmitt D. Fu X. Thomson L. Fox P.L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease J. Clin. Investig. 2004 114 529 541 10.1172/JCI200421109 15314690 PMC503769 · DOI
  111. [122]Holzer M. Gauster M. Pfeifer T. Wadsack C. Fauler G. Stiegler P. Koefeler H. Beubler E. Schuligoi R. Heinemann A. Protein carbamylation renders high-density lipoprotein dysfunctional Antioxid. Redox Signal. 2011 14 2337 2346 10.1089/ars.2010.3640 21235354 PMC3380531 · DOI
  112. [124]Nguyen Dinh Cat A. Montezano A.C. Burger D. Touyz R.M. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature Antioxid. Redox Signal. 2013 19 1110 1120 10.1089/ars.2012.4641 22530599 PMC3771549 · DOI
  113. [125]Higashi Y. Kihara Y. Noma K. Endothelial dysfunction and hypertension in aging Hypertens. Res. 2012 35 1039 1047 10.1038/hr.2012.138 22972557 · DOI
  114. [126]Montezano A.C. Touyz R.M. Reactive oxygen species, vascular noxs, and hypertension: Focus on translational and clinical research Antioxid. Redox Signal. 2014 20 164 182 10.1089/ars.2013.5302 23600794 PMC3880913 · DOI
  115. [127]Koya D. King G.L. Protein kinase C activation and the development of diabetic complications Diabetes 1998 47 859 866 10.2337/diabetes.47.6.859 9604860 · DOI
  116. [128]Volpe C.M.O. Villar-Delfino P.H. Dos Anjos P.M.F. Nogueira-Machado J.A. Cellular death, reactive oxygen species (ROS) and diabetic complications Cell Death Dis. 2018 9 119 10.1038/s41419-017-0135-z 29371661 PMC5833737 · DOI
  117. [129]Tomino Y. Hagiwara S. Gohda T. AGE–RAGE interaction and oxidative stress in obesity related renal dysfunction Kidney Int. 2011 80 133 135 10.1038/ki.2011.86 21720304 · DOI
  118. [130]Basta G. Lazzerini G. Del Turco S. Ratto G.M. Schmidt A.M. De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products Arterioscler. Thromb. Vasc. Biol. 2005 25 1401 1407 10.1161/01.ATV.0000167522.48370.5e 15845907 · DOI
  119. [131]Tan K.C. Chow W.S. Ai V.H. Metz C. Bucala R. Lam K.S. Advanced glycation end products and endothelial dysfunction in type 2 diabetes Diabetes Care 2002 25 1055 1059 10.2337/diacare.25.6.1055 12032114 · DOI
  120. [132]Bae J.P. Lage M.J. Mo D. Nelson D.R. Hoogwerf B.J. Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009–2011 J. Diabetes Complic. 2016 30 212 220 10.1016/j.jdiacomp.2015.11.016 26689451 · DOI
  121. [133]Flock M.R. Green M.H. Kris-Etherton P.M. Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol Adv. Nutr. 2011 2 261 274 10.3945/an.111.000422 22332058 PMC3090171 · DOI · Paper page
  122. [134]Farb M.G. Ganley-Leal L. Mott M. Liang Y. Ercan B. Widlansky M.E. Bigornia S.J. Fiscale A.J. Apovian C.M. Carmine B. Arteriolar function in visceral adipose tissue is impaired in human obesity Arterioscler. Thromb. Vasc. Biol. 2012 32 467 473 10.1161/ATVBAHA.111.235846 22095978 PMC3262114 · DOI
  123. [135]Furukawa S. Fujita T. Shimabukuro M. Iwaki M. Yamada Y. Nakajima Y. Nakayama O. Makishima M. Matsuda M. Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome J. Clin. Investig. 2004 114 1752 1761 10.1172/JCI21625 15599400 PMC535065 · DOI · Paper page
  124. [136]Fujita K. Nishizawa H. Funahashi T. Shimomura I. Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome Circ. J. 2006 70 1437 1442 10.1253/circj.70.1437 17062967 · DOI
  125. [137]Morelli N.R. Scavuzzi B.M. Miglioranza L.H.D.S. Lozovoy M.A.B. Simão A.N.C. Dichi I. Metabolic syndrome components are associated with oxidative stress in overweight and obese patients Arch. Endocrinol. Metab. 2018 62 309 318 10.20945/2359-3997000000036 29791650 PMC10118790 · DOI
  126. [138]Yokota T. Kinugawa S. Yamato M. Hirabayashi K. Suga T. Takada S. Harada K. Morita N. Oyama-Manabe N. Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in patients with metabolic syndrome Diabetes Care 2013 36 1341 1346 10.2337/dc12-1161 23393211 PMC3631820 · DOI
  127. [139]Pradhan A.D. Manson J.E. Rifai N. Buring J.E. Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 2001 286 327 334 10.1001/jama.286.3.327 11466099 · DOI · Paper page
  128. [140]Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults Diabetes Care 1999 22 1971 1977 10.2337/diacare.22.12.1971 10587828 · DOI
  129. [141]Festa A. D’Agostino R. Jr. Howard G. Mykkanen L. Tracy R.P. Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS) Circulation 2000 102 42 47 10.1161/01.CIR.102.1.42 10880413 · DOI
  130. [142]Sesso H.D. Buring J.E. Rifai N. Blake G.J. Gaziano J.M. Ridker P.M. C-reactive protein and the risk of developing hypertension JAMA 2003 290 2945 2951 10.1001/jama.290.22.2945 14665655 · DOI
  131. [143]Pearle A.D. Scanzello C.R. George S. Mandl L.A. DiCarlo E.F. Peterson M. Sculco T.P. Crow M.K. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis Osteoarthr. Cartil. 2007 15 516 523 10.1016/j.joca.2006.10.010 17157039 · DOI · Paper page
  132. [144]Daghestani H.N. Kraus V.B. Inflammatory biomarkers in osteoarthritis Osteoarthr. Cartil. 2015 23 1890 1896 10.1016/j.joca.2015.02.009 26521734 PMC4630669 · DOI
  133. [145]Biswas S.K. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid. Med. Cell Longev. 2016 2016 5698931 10.1155/2016/5698931 26881031 PMC4736408 · DOI
  134. [146]Fröhlich M. Imhof A. Berg G. Hutchinson W.L. Pepys M.B. Boeing H. Muche R. Brenner H. Koenig W. Association between C-reactive protein and features of the metabolic syndrome: A population-based study Diabetes Care 2000 23 1835 1839 10.2337/diacare.23.12.1835 11128362 · DOI
  135. [147]Albert M.A. Glynn R.J. Ridker P.M. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score Circulation 2003 108 161 165 10.1161/01.CIR.0000080289.72166.CF 12835213 · DOI
  136. [148]Cottone S. Mulè G. Nardi E. Vadalà A. Guarneri M. Briolotta C. Arsena R. Palermo A. Riccobene R. Cerasola G. Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension Am. J. Hypertens. 2006 19 313 318 10.1016/j.amjhyper.2005.09.005 16500520 · DOI
  137. [149]Kim M. Kim M. Yoo H.J. Lee S.Y. Lee S.H. Lee J.H. Age-specific determinants of pulse wave velocity among metabolic syndrome components, inflammatory markers, and oxidative stress J. Atheroscler. Thromb. 2018 25 178 185 10.5551/jat.39388 28740031 PMC5827087 · DOI
  138. [150]Verma S. Wang C.H. Li S.H. Dumont A.S. Fedak P.W. Badiwala M.V. Dhillon B. Weisel R.D. Li R.K. Mickle D.A. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis Circulation 2002 106 913 919 10.1161/01.CIR.0000029802.88087.5E 12186793 · DOI

Cited by

Sorted by citations

Authors
Ito, F., Sono, Y., & Ito, T.
Affiliations
  • The Institute of Prophylactic Pharmacology, Shinagawa, Tokyo 140-0001, Japan
  • Sunstar (Japan) (JP)
  • Kyoto Prefectural University of Medicine (JP)
Corresponding author
Ito, Fumiaki
ORCID
Venue
Antioxidants
Publisher
MDPI AG
Published
2019-03-25
Volume
8
Issue
3
Pages
72
ISSN
2076-3921 (ISSN-L)
DOI
10.3390/antiox8030072
PMC
PMC6466575
OpenAlex
W2924534120
Cited by
535
References
10
Citations by year
2026: 48 · 2025: 76 · 2024: 105 · 2023: 100 · 2022: 77 · 2021: 70 · 2020: 48 · 2019: 11
FWCI
4.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Antioxidants (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Japan Society for the Promotion of Science (15K01383)
Topics
  • Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
Keywords
lipid peroxidation, oxidative stress, biomarkers, diabetes mellitus, atherosclerosis, chronic inflammation, endothelial dysfunction, reactive oxygen species, advanced glycation end products, cardiovascular disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review